A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Acute Anterior ST-Segment Elevation Myocardial Infarction

In brief

This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to standard clinical care in Chinese patients with acute anterior ST-segment elevation myocardial infarction (STEMI) who are planned for primary percutaneous coronary intervention (pPCI).

Key facts

Study ID

NCT07306182

Run by

Beijing Sungen Biomedical Technology Co., Ltd

People needed

210

Starts

2026-03-09

Expected to finish

2027-10-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-79 years of age (including boundary values), male or female;
• Anterior wall STEMI: (a) history of persistent chest pain/precordial discomfort (>30 minutes); (b) upon admission, the ECG must meet the following requirements: i.For male participants >40 years old, ST-segment elevation ≥2 mm in leads V2 and V3; ii.For male participants ≤40 years old, ST-segment elevation ≥2.5 mm in leads V2 and V3; iii.For female participants, ST-segment elevation ≥1.5 mm in leads V2 and V3; If clinical symptoms of (a) are atypical, then (c) a positive point-of-care troponin test is required.
• Planned for pPCI treatment;
• Assessed as being able to complete dosing within 6 hours of the onset of persistent chest pain/precordial discomfort symptoms;
• The participant or their legal guardian fully understands the objectives, nature, methods, and potential adverse reactions of the study, voluntarily agrees to participate, and has signed the informed consent form (ICF).

You may not qualify if…

• History of the following cardiac conditions:
• History of myocardial infarction, coronary revascularization (including percutaneous coronary intervention [PCI] and coronary artery bypass grafting [CABG], etc.);
• History of cardiopulmonary resuscitation;
• History of stroke within 6 months;
• Presence of severe cardiac structural abnormalities such as aortic dissection, and ventricular aneurysm;
• Patients who have received thrombolysis;
• Patients with a life expectancy of less than 1 year;
• Febrile infection requiring systemic treatment within 2 weeks prior to screening;
• Concomitant left bundle branch block;
• Cardiogenic shock or hemodynamic instability;
• Concomitant severe arrhythmia (including high-degree atrioventricular block, sick sinus syndrome, sustained ventricular tachycardia, etc.) or implanted cardiac pacemaker;
• Definitive diagnosis of acute heart failure (Killip classification ≥ III; for details on Killip classification, see Appendix);
• Unable to undergo cardiac magnetic resonance (CMR) imaging according to the study protocol, or known allergy to any radiocontrast agent;

Where it is running

• Shanghai East Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.